XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
12. Restructuring Costs (Notes)
3 Months Ended
Mar. 31, 2021
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTSIn February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $71.2 million as of March 31, 2021 consisted of $35.2 million recorded in Accrued payroll and employee benefits and $36.0 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional adjustments and future cash payments could occur in relation to the restructuring actions.
The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2020:$— $— $— 
Charged to expense - employee termination benefits12.9 62.7 75.6 
Cash payments(0.1)(1.9)(2.0)
Foreign currency translation gains(0.4)(2.0)(2.4)
Balances as of March 31, 2021:$12.4 $58.8 $71.2